The role of polyols in the pathophysiology of hypergalactosemia

European Journal of Pediatrics

Volumn 154, Issue 2 Supplement, 1995, Pages

  Berry, Gerard T ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTITOL; INOSITOL; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; GALACTOKINASE; GALACTOSE; POLYOL;

ANIMAL; GALACTOSEMIA; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; DOG; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMAL; GALACTITOL; GALACTOSEMIAS; HUMAN; INOSITOL;

EID: 0029116445     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/BF02143805     Document Type: Article

References (131)

1. Effect of an aldosereductase inhibitor. CT-112, on healing of the corneal epithelium in galactose-fed rats
2. induction of aldose reductase and sorbitol in renal inner medullary cells by elevated extracellular NaCl
3. Galactose feeding causes glomerular hyperfusion: Prevention by aldose reductase inhibition
4. Changes in CDP-diglyceride: inositol transferase activity during rabbit lung development
5. Ophthalmic findings in classical galactosaemia-prospective study
6. Computed tomographic demonstration of cerebral edema in a child with galactosemia
7. Inositol phosphates and cell signalling
8. Myoinositol transport and metabolism in fetal bovine aortic endothelial cells
9. The effect of dietary fruits and vegetables on urinary galactitol excretion in galactose-1-phosphate uridyltransferase deficiency
10. The effect of glucose and galactose toxicity on myoinositol transport and metabolism in human skin fibroblasts in culture
11. Sorbinil effect on sugart cataract progression and recovery: An initial study
12. Sorbinil protection of lens protein components and cell hydration during diabetic cataract formation
13. Diminished sugar cataractogeneesis by quercetin
14. Synergism of sorbinil and normal diet on reversal of stage-II cataract
15. The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases
16. Effect of lactation in a mother with galactosemia
17. Galactosemia in an infant with cataracts
18. Role of aldose reductase and sorbitol in maintaining the medullary intracellular milieu
19. Coexistence of nerve conduction deficit with increased Na+, K+-ATPase activity in galactose-fed mice implications for polyol pathway and diabetic neuropathy
20. Statil-sensitive polyol formation in nerve of galactose-fed mice
21. Muscle and nerve dysfunction in rats with experimental galactosemia
22. Galactose ingestion increases vascular permeability and collagen solubility in normal male rats
23. Role of nonenzymatic glycosylation in experimental cataract formation
24. Cloning and sequence determination of human placental aldose reductase gene
25. Characterization of a salt-extractable phosphatidylinositol synthase from rat pituitary-tumor membranes
26. Functional and structural alterations of the glomerular permeability barrier in experimental galactosemia
27. Sorbinil does not prevent galactoseinduced glomerular capillary basement membrane thickening in the rat
28. Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: A light microscopic study
29. The effects of sorbinil, an aldose reductase inhibitor, on the cornel endothelium in galactosemic dogs
30. Abnormal galactose metabolism in man
31. Polyol accumulation in galactosemic and diabetic rats: Control by an aldose reductase inhibitor
32. Tolrestat pharmacokinetics in rat peripheral nerve
33. D-myo-inositol-1-phosphate as product of cyclization of glucose 6-phosphate and substrate for a specific phosphatase in rat testis
34. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs
35. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs
36. Galactose-induced retinal capillary basement membrane thickening: Prevention by sorbinil
37. Cerebral cortical capillary basement membrane thickening in galactosaemic rats
38. Mechanism of development and posible prevention of sugar cataracts
39. Hyperglycemia, polyol metabolism and complications of diabetes mellitus
40. Molecular cloning of cDNA coding for kidney aldose reductase: Regulation of specific mRNA accumulation by NaCl-mediated osmotic stress
41. Role of organic osmolytes in adaptation of renal cells to high osmolarity
42. Galactosemia: How does long-term treatment change the outcome?
43. Nucleotide sequence of cDNA for human aldose reductase
44. Structure of the human aldose reductase gene
45. Sorbitol, phosphoinositides, and sodium-potassium-ATPsse in the pathogenesis of diabetic complications
46. Galactose neuropathy: Structural changes evaluated by nuclear magnetic resonance spectroscopy
47. Cloning and prokaryotic expressions of a biologically active human placental aldose reductase
48. Control of brain volume during hyperosmolar and hypoosmolar conditions
49. The biosynthesis of free and phosphatide myo-inositol from glucose by mammalian tissue slices
50. Regulation of renal cell organic osmolyte transport by tonicity
51. Isolation and properties of lens aldose reductase
52. Prevention of galactose cataract by pyruvate
53. Altered aldose reductase gene regulation in cultured human retinal pigment epithelial cells
54. Le mechanisme de la formation du fructose seminal et du fructose foetal
55. Osmotic stress induces aldose reductase in glomerular endothelial cells
56. Metabolism and function of myo-inositol and inositol phospholipids
57. Reversal of galactose cataract with sorbinil in rats
58. Prevention and reversal of galactose cataract in rats with topical sorbinil
59. Pseudotumor cerebri in galactosemia
60. Dietary restriction of maternal lactose intake does not prevent accumulation of galactitol in the amniotic fluid of fetuses affected with galactosemia
61. Prevention of pericyte ghost formation in retinal capillaries of galactose-fed dogs by aldose reductase inhibitors
62. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors
63. Induction of aldose reductase expression in rat kidney mesangial cells and Chinese hamster ovary cells under hypertonic conditions
64. Effects of novel hydantoin derivatives with aldose reductase inhibiting activity on galactose-induced cataract in rats
65. Reversal of Stage II galactose catarct by combination of sorbinil and normal diet
66. Retinal polyol and myo-inositol in galactosemic dogs given an aldose-reductase inhibitor
67. Mechanisms initiating cataract formation. Proctor Lecture
68. The effect of aldose reductase inhibitor on the galactose exposed rabbit lens
69. The involvement of aldose reductase in diabetic complications
70. Adenosine triphosphatase in nerves and ganglia of rats with streptozotocin-induced diavetes or galactosemia; effects of aldose reductase inhibition
71. Permeability changes in blood-retinal barrier of galactosemic rats are prevented by aldose reductase inhibitors
72. Galactokinase deficiency presenting as pseudotumor cerebri
73. Sodium, potassium adenosine triphosphatase activity in peripheral nerve tissue of galactosaemic rats. Effects of aldose reductase inhibition
74. The prevention of biochemical changes in lens, retina and nerve of galactosemic dogs by the aldose reductase inhibitor AL01576
75. Purification, structure and catalytic properties of L-myo-Inositol-1-phosphate synthase from rat testis
76. Pressure-induced inhibition of fast axonal transport of proteins in the rabbit vagus nerve in galactose neuropathy: prevention by an aldose reductase inhibitor
77. Aldose reductase inhibition prevents galactose-induced ovarian dysfunction in the Sprague-Dawley rat
78. Edema and increased endoneurial sodium in galactose neuropathy. Reversal with an aldose reductase inhibitor
79. Schwann cell injury is attenuated by aldose reductase inhibition in galactose intoxication
80. Non-tryptophan fluorescence and high molecular weight protein formation in lens crystallins of rats with chronic galactosemia: prevention by the aldose reductase inhibitor sorbinil
81. Turnover of inositol phospholipids and signal transduction
82. Depletion of myo-inositol and amino acids in galactosemic neuropathy
83. Effects of an aldose reductase inhibitor, 1-[p-Bromophenyl)-sulfonyl]hydantoin, on cataract formation and tissue polyol levels in galactosemic rats
84. Effect of gossypin, a flavonoid, on the formation of galactose-induced cataracts in rats
85. CP-45,634: A novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats
86. Plasma 1,5-anhydroglucitol in experimental galactosemia in the rat
87. Effects of magnesium on galactose-induced cataract formation and lens aldose reductase activity in rats
88. Tissue-specific effects of aldose reductase inhibition on fluorescence and cross-linking of extracellular matrix in chronic galactosemia — Relationship to pentosidine cross-links
89. Retinal capillaries: Basement membrane thickening by galactosemia prevented with aldose reductase inhibitor
90. Prevention of basement membrane thickening in retinal capillares by a novel inhibitor of aldose reductase, tolrestat
91. Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor
92. Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor
93. Urinary galactitol in galactosemic patients
94. Maturation of aldose reductase expression in the neonatal rat inner medulla
95. Long-term outcome in 134 patients with galactosemia
96. Disorders of galactose metabolism
97. The development of electroretinogram abnormalities and the possible role of polyol pathway activity in diabetic hyperglycemia and galactosemia
98. Kinetic evidence for compartmetalization of myo-inositol in hepatocytes
99. The effects of a new aldose reductase inhibitor (Tolrestat) in galactosemic and diabetic rats
100. Prevention of cataract development in severely galactosemic rats by the aldose reductase inhibitor, tolrestat
101. Mechanism of glucose-induced (Na+, K+)-ATPase inhibition in aortic wall of rabbits
102. Polyol pathway activity in nervous tissues of diabetic and galactosefed rats: Effect of dietary galactose withdrawal or tolrestat intervention therapy
103. Activation of human erythrocyte, brain: aorta, muscle, and ocular tissue aldose reductase
104. Galactose and cataract
105. Movement of regenerated lens epithelial cells in 50% galactose cataract and an aldose reductase inhibitor
106. myo-Inositol: A newly identified nonnitrogenous osmoregulatory molecule in mammalian brain
107. Discordant effects of the aldose reductase inhibitor, sorbinil, on vascular structure and function in chronically diabetic and galactosemic rats
108. Increased ocular blood flow and 125I-albumin permeation in galactose-fed rats: inhibition by sorbinil
109. Prefeeding of aldose reductase inhibitor inhibits galactose cataract
110. Medium tonicity regulates expression of the Na+-and Cl-dependent betaine transporter in Madin-Darby canine kidney cells by increasing transcription of the transporter gene
111. Inhibition of galactose-induced alterations in ocular lens with sorbinil
112. Prefeeding of aldose reductase inhibitor and galactose cataractogenesis
113. In utero and milk-mediated effect of aldose reductase inhibitor on galactose cataracts
114. Aldose reductase inhibitors and galactose toxicity in neonatal and maternal rat lenses
115. Formation of polyols by the lens of the rat with ‘sugar’ cataract
116. Lens changes in a galactosemic fetus
117. Topical treatment of galactose cataracts
118. Ultrastructural localization of blood-retinal barrier breakdown in diabetic and galactosemic rats
119. Electron microscopic immunocytochemical evidence for the mechanism of blood-retinal barrier breakdown in galactosemic rats and its association with aldose reductase expression and inhibition
120. Increased intracranial pressure in galactosemia
121. Prevention of nerve edema and increased blood-nerve barrier permeability-surface area product in galactosemic rats by aldose reductase or thromboxane synthetase inhbitors
122. Characterization of the human aldose reductase gene promoter
123. Inhibition of lens aldose reductase (A.R.) by 7-dimethylsulfamoyl-xanthone-2-carboxylic acid (RS 7535)
124. Does galactose feeding provide a valid model of consequences of exaggerated polyol-pathway flux in peripheral nerve in experimental diabetes?
125. Hyperglycemic pseudohypoxia and diabetic complications
126. An unlikely sugar substrate site in the 1.65 Å structure of the human aldose reductase holoenzyme implicated in diabetic complications
127. Does a common mechanism induce the diverse complications of diabetes?
128. Immunohistochemical staining and enzyme activity measurements show myoinositol-1-phosphate synthase to be localized in the vasculature of brain